Chemical Name: (2S)-2-(4-(((2,4-diamino-4a,8a-dihydropteridin-6-yl)methyl)(methyl)amino)benzamido)-5-methoxy-5-oxopentanoic acid
Smiles: NC1=NC(N=CC(CN(C)C2=CC=C(C(N[C@@](CCC(OC)=O)(C(O)=O)[H])=O)C=C2)=N3)=C3C(N)=N1
Inchi: InChI=1S/C28H29N9O6/c1-36(14-17-13-31-24-22(32-17)23(29)34-28(30)35-24)18-7-5-16(6-8-18)26(41)37(2)19-9-3-15(4-10-19)25(40)33-20(27(42)43)11-12-21(38)39/h3-10,13,20H,11-12,14H2,1-2H3,(H,33,40)(H,38,39)(H,42,43)(H4,29,30,31,34,35)/t20-/m0/s1
Identification and Quantitation of Impurities in Methotrexate
dulal c. chatterji, altice g. frazier, and joseph f. gallell
Journal of Pharmaceutical Sciences Volume 67, Issue 5, May 1978, Pages 622-624
determination of methotrexate and its major metabolite, 7_hydroxymethotrexate, using capillary zone electrophoresis and laser-induced fluorescence detection
mark c. roach, philippe gozel and richard n. zare
Journal of Chromatography, 426 (1988) 129-140
Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples
Forough Karami , Sara Ranjbar , Younes Ghasemi , Manica Negahdaripour
Journal of Pharmaceutical Analysis 9 (2019) 373-391
Perspectives of Methotrexate-Based Radioagents for Application in Nuclear Medicine
Paweł Krzysztof Halik,* Przemysław Kozmin ́ ski, and Ewa Gniazdowska
Mol. Pharmaceutics 2021, 18, 1, 33–43